Atopic dermatitis (AD) presents as a long-term, recurring inflammatory disorder of the skin, and its characteristic itching significantly affects patients' daily living standards. The research was ...

Ivarmacitinib, a selective oral Janus kinase 1 inhibitor, significantly improved signs and symptoms in patients with moderate to severe atopic dermatitis (AD) and showed a favorable safety profile ...

However, they cautioned that there were no health-related quality of life, respiratory symptoms, or lung function benefits as previously seen with dupilumab (Dupixent) in a similar COPD population ...

"As Atopic Dermatitis is an immunologically and phenotypically heterogenous disease, which can involve both the innate and adaptive parts of the immune system, targeting the broad IL-1 family of ...

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent ... several type 2 inflammatory diseases like atopic dermatitis and asthma and has demonstrated ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

Racial representation in recent atopic dermatitis trials has largely been representative of the U.S. population. Black individuals should be represented more because of disease prevalence rates.

Psoriasis has many imitators, but one that comes very close is seborrheic dermatitis. That’s because both conditions can cause red, scaly, inflamed patches on your skin. To tell the two apart ...

Sanofi post­ed a strong set of first-quar­ter re­sults Thurs­day morn­ing, with its re­com­bi­nant fac­tor drug Al­tuvi­i­io on track to be­come a block­buster drug and its … ...

In 2024, Dupixent sales came in at $14.1 billion, which was an increase of 22% from 2023. Dupixent’s trajectory contributed heavily to Sanofi’s strong quarterly performance.

Sales for the quarter grew by 11% to 9.9 billion euros ($11.3 billion), with growth driven by a host of new product launches and the continuing rise of immunology drug Dupixent (dupilumab). Business ...